BioLineRx Future Growth
Future criteria checks 2/6
BioLineRx is forecast to grow earnings and revenue by 24.9% and 73.4% per annum respectively while EPS is expected to grow by 113.8% per annum.
Key information
24.9%
Earnings growth rate
113.8%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 73.4% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Apr 2024 |
Recent future growth updates
No updates
Recent updates
BioLineRx stock slips on $15M securities offering
Sep 19BioLineRx files for FDA approval of motixafortide in stem cell mobilization
Sep 12biolinerx GAAP EPS of -$0.01 beats by $0.08
Aug 16BioLineRx, GenFleet to co-develop Motixafortide treatment for a type of pancreatic cancer
Jun 29BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
Jun 30biolinerx EPS beats by $0.17
May 26BioLineRx (BLRX) shares rocket 73% on positive Motixafortide data in multiple myeloma
May 04BioLineRx jumps 22% on promising triple combination data of motixafortide in pancreatic cancer
Dec 16biolinerx EPS beats by $0.32
Nov 23BioLineRx launches early-stage study with lead asset in COVID-19 related respiratory distress
Nov 18BioLineRx launches mid-stage combo study in first-line pancreatic cancer
Oct 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 28 | -37 | N/A | N/A | 2 |
| 12/31/2024 | 14 | -47 | N/A | N/A | 2 |
| 12/31/2023 | 5 | -61 | -23 | -23 | N/A |
| 9/30/2023 | N/A | -52 | -34 | -33 | N/A |
| 6/30/2023 | N/A | -43 | -33 | -32 | N/A |
| 3/31/2023 | N/A | -32 | -29 | -29 | N/A |
| 12/31/2022 | N/A | -25 | -27 | -26 | N/A |
| 9/30/2022 | N/A | -24 | -26 | -26 | N/A |
| 6/30/2022 | N/A | -22 | -23 | -22 | N/A |
| 3/31/2022 | N/A | -22 | -23 | -23 | N/A |
| 12/31/2021 | N/A | -27 | -24 | -24 | N/A |
| 9/30/2021 | N/A | -35 | -24 | -24 | N/A |
| 6/30/2021 | N/A | -34 | -24 | -24 | N/A |
| 3/31/2021 | N/A | -34 | -23 | -23 | N/A |
| 12/31/2020 | N/A | -30 | -23 | -23 | N/A |
| 9/30/2020 | N/A | -28 | -23 | -23 | N/A |
| 6/30/2020 | N/A | -27 | -24 | -24 | N/A |
| 3/31/2020 | N/A | -26 | -25 | -25 | N/A |
| 12/31/2019 | N/A | -25 | -23 | -23 | N/A |
| 9/30/2019 | N/A | -21 | -33 | -22 | N/A |
| 6/30/2019 | N/A | -24 | -32 | -22 | N/A |
| 3/31/2019 | N/A | -23 | -32 | -22 | N/A |
| 12/31/2018 | N/A | -23 | -34 | -24 | N/A |
| 9/30/2018 | N/A | -25 | -26 | -25 | N/A |
| 6/30/2018 | N/A | -26 | -26 | -26 | N/A |
| 3/31/2018 | N/A | -26 | -24 | -24 | N/A |
| 12/31/2017 | N/A | -24 | -25 | -21 | N/A |
| 9/30/2017 | N/A | -21 | N/A | -18 | N/A |
| 6/30/2017 | N/A | -18 | N/A | -15 | N/A |
| 3/31/2017 | N/A | -17 | N/A | -14 | N/A |
| 12/31/2016 | N/A | -16 | N/A | -15 | N/A |
| 9/30/2016 | N/A | -15 | N/A | -14 | N/A |
| 6/30/2016 | N/A | -13 | N/A | -14 | N/A |
| 3/31/2016 | N/A | -14 | N/A | -15 | N/A |
| 12/31/2015 | N/A | -14 | N/A | -14 | N/A |
| 9/30/2015 | N/A | -15 | N/A | -16 | N/A |
| 6/30/2015 | N/A | -14 | N/A | -15 | N/A |
| 3/31/2015 | N/A | -13 | N/A | -16 | N/A |
| 12/31/2014 | N/A | -11 | N/A | -16 | N/A |
| 9/30/2014 | N/A | -11 | N/A | -15 | N/A |
| 6/30/2014 | N/A | -16 | N/A | -16 | N/A |
| 3/31/2014 | N/A | -16 | N/A | -18 | N/A |
| 12/31/2013 | N/A | -17 | N/A | -20 | N/A |
| 9/30/2013 | N/A | -20 | N/A | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLRX's revenue (73.4% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: BLRX's revenue (73.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BLRX's Return on Equity is forecast to be high in 3 years time